Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

If Trump wants to improve Americans’ health, as he says, expanding coverage of weight-loss drugs should be a priority. With ...

For the first time in a decade, obesity in the U.S. is declining — and a new study suggests it’s because of wildly popular ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 491.86% and ...

Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...

Additionally, Lilly CEO David Ricks said the drugmaker will start testing its GLP-1 medications as treatments for alcohol and ...

Eli Lilly has partnered with the telehealth company Ro to expand access to single-dose vials of its popular weight loss drug Zepbound. Through Ro's platform, eligible patients can receive ...

Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an ...

Eli Lilly ( LLY -1.72%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its ...

Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...